Seer (SEER) AI Stock Analysis

• Market Cap: $124.75M
• Dividend Yield: N/A
• Average Volume (3M): 94.67K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.45
• Revenue Growth: -1.02%
• EPS Growth: -8.59%
• Country: US
• Employees: 134
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 54,801,254
• 10 Day Avg. Volume: 82,260
• 30 Day Avg. Volume: 94,675
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.91
• Enterprise Value/Revenue: -7.51
• Enterprise Value/Gross Profit: -18.64
• Enterprise Value/Ebitda: 1.25
• 1Y Price Target: $3.00
• Price Target Upside: 49.25% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 52 Neutral
• Price Target: $2.00 ▼(-0.50% Downside)

Seer's overall stock score is primarily influenced by its mixed financial performance, with strengths in equity but weaknesses in profitability and cash flow. Technical indicators suggest bearish momentum, and valuation concerns arise from its negative P/E ratio. The earnings call provides some optimism with strong revenue growth and strategic initiatives, but challenges remain.

Positive Factors

Commercial Initiatives

SEER has experienced strong traction from its STAC program as sample volumes increased and service revenue grew by 28%.

Operational Success

The number of instruments shipped in the quarter matched the total for the entire previous year, demonstrating strong demand and operational performance.

Revenue Performance

2Q revenue of $4.1M was approximately 8% ahead of $3.8M consensus, with strong product revenue of $2.7M despite the difficult macro for capital expenditure.

Negative Factors

Government Funding Uncertainty

Revenue guidance remains cautious due to uncertainty around government funding and US tariff policies affecting market visibility.

Instrument Sales Decline

Seer, Inc. saw a decline in product revenue driven by a decrease in instrument sales due to pressure on capital expenditure budgets and longer sales cycles.

Market Conditions

Challenging market conditions across Pharma and A&G continue to temper demand and weigh on the stock's performance.

Seer Business Overview & Revenue Model

Company Description

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

How the Company Makes Money

Seer generates revenue through the sale of its Proteograph Product Suite and related consumables, which are essential for conducting proteomic analyses. The company's revenue model primarily includes the direct sale of these products to research institutions, pharmaceutical companies, and academic labs. Additionally, Seer may engage in strategic partnerships and collaborations with other biotech firms and research organizations to expand its market reach and enhance its technological offerings. Through these collaborations, Seer can also generate revenue through licensing agreements and joint development projects.

Seer Financial Statement Overview

Summary

Seer's financial performance is mixed, with strengths in equity and capital structure, but significant challenges in profitability and cash flow management. The company’s modest revenue growth and strong equity position are offset by a negative net profit margin and inconsistent revenue growth.

Income Statement

Seer shows modest revenue growth in the TTM, with a Gross Profit Margin of 40.3%. However, the company faces significant challenges with profitability, as evidenced by a negative Net Profit Margin of -56.6% and negative EBIT and EBITDA margins. Revenue growth has been inconsistent, indicating potential volatility and challenges in sustaining revenue growth.

Balance Sheet

The company has a strong equity position with a low Debt-to-Equity Ratio of 0.08, indicating low leverage. The Equity Ratio stands at 89.6%, which reflects a solid capital structure. However, the consistent negative net income impacts Return on Equity, limiting the potential returns to shareholders.

Cash Flow

Seer has been facing negative Free Cash Flow, although there is a small improvement in the growth rate. The Operating Cash Flow to Net Income ratio reflects challenges in converting income into cash flow, a concern for ongoing operations. The cash flow metrics indicate a reliance on financing activities to support business operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	13.95M	15.18M	14.69M	6.39M	656.00K
Gross Profit	6.83M	7.03M	6.74M	3.19M	656.00K
EBITDA	-93.92M	-97.89M	-93.29M	-68.59M	-31.17M
Net Income	-86.60M	-86.28M	-88.70M	-68.63M	-31.17M
Balance Sheet
Total Assets	366.60M	436.27M	487.93M	539.14M	442.32M
Cash, Cash Equivalents and Short-Term Investments	236.41M	316.22M	421.24M	400.07M	431.86M
Total Debt	25.96M	28.26M	29.87M	23.32M	0.00
Total Liabilities	39.03M	39.37M	40.94M	36.22M	10.71M
Stockholders Equity	327.57M	396.90M	446.99M	502.92M	431.61M
Cash Flow
Free Cash Flow	-49.69M	-66.37M	-71.05M	-53.27M	-25.36M
Operating Cash Flow	-46.11M	-59.06M	-60.78M	-46.35M	-20.83M
Investing Cash Flow	65.86M	37.90M	-122.72M	-170.88M	-34.56M
Financing Cash Flow	-11.49M	452.00K	3.89M	116.63M	371.49M

Seer Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SEER, the sentiment is Negative. The current price of 2.01 is below the 20-day moving average (MA) of 2.13, below the 50-day MA of 2.12, and below the 200-day MA of 2.14, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 35.49 is Neutral, neither overbought nor oversold. The STOCH value of 11.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SEER.

Seer Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADCT	53 Neutral	$273.73M	―	123.38%	―	10.49%	47.31%
SEER	52 Neutral	$124.75M	―	-25.25%	―	-1.02%	-8.59%
FDMT	52 Neutral	$280.26M	―	-32.97%	―	―	―
SLN	49 Neutral	$264.96M	―	-99.23%	―	-40.10%	-16.60%
Sector *	47 Neutral	C$188.09M	-2.68	-23.77%	3.19%	17.01%	2.49%
VOR	33 Underperform	$272.41M	―	-125.43%	―	―	2.98%
KLRS	28 Underperform	$42.68M	―	-41.96%	―	―	72.12%

Seer Corporate Events

Seer Faces Nasdaq Compliance Challenge After Annual Meeting

On July 7, 2025, Seer, Inc. informed Nasdaq that it would no longer comply with Nasdaq Listing Rule 5605(c)(2)(A) following its 2025 Annual Meeting of Stockholders. The company plans to utilize the cure period to address the composition of its Audit Committee to regain compliance. During the Annual Meeting, stockholders elected six directors and ratified Deloitte & Touche LLP as the independent accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (SEER) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Seer stock, see the SEER Stock Forecast page.